Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium oxide plus triple-strain probiotic for chronic constipation
jRCTs051250172Recruiting
- Sponsor
- TOA Biopharma
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of magnesium oxide and Biosly in functional constipation (FC) and irritable bowel syndrome (IBS), sponsored by TOA Biopharma. Started Jan 2026; status: recruiting.
02
Drugs
magnesium oxideBiosly
03
Conditions
functional constipation (FC)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on jRCTs051250172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250172.